PE88699A1 - Formas de dosificacion de liberacion sostenida de sertralina - Google Patents
Formas de dosificacion de liberacion sostenida de sertralinaInfo
- Publication number
- PE88699A1 PE88699A1 PE1998000572A PE00057298A PE88699A1 PE 88699 A1 PE88699 A1 PE 88699A1 PE 1998000572 A PE1998000572 A PE 1998000572A PE 00057298 A PE00057298 A PE 00057298A PE 88699 A1 PE88699 A1 PE 88699A1
- Authority
- PE
- Peru
- Prior art keywords
- sertraline
- compressed
- sustained release
- dosage forms
- mga
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
- A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
- A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Child & Adolescent Psychology (AREA)
- Pain & Pain Management (AREA)
- Addiction (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
SE REFIERE A UNA FORMA DE DOSIFICACION QUE LIBERA SERTRALINA A UNA VELOCIDAD NO SUPERIOR A 0,8 mgA/h/Kg, NO LIBERANDO MAS DEL 70% DE SERTRALINA EN LA PRIMERA HORA, Y LUEGO LIBERANDOLA A UNA VELOCIDAD DE 0,02 mgA/h/Kg LA LIBERACION SOSTENIDA SE DESENCADENA POR EL pH. LA SERTRALINA SE ENCUENTRA COMO BASE LIBRE, CLORHIDRATO, ACETATO, ASPARTATO O LACTATO; SIENDO SENSIBLE A LAS ENZIMAS. LAS FORMAS DE DOSIFICACION SE PRESENTAN COMO COMPRIMIDO DE MATRIZ QUE PERMANECE INTACTO DURANTE EL PERIODO DE LIBERACION SOSTENIDA, COMPRIMIDO DE MATRIZ DISGREGABLE, COMPRIMIDO DE MATRIZ PARCIALMENTE RECUBIERTO CON UN POLIMERO QUE IMPIDE LA LIBERACION DE SERTRALINA, COMPRIMIDO OSMOTICO, COMPRIMIDO CON HIDROGEL, SISTEMA MULTIPARTICULAR RECUBIERTO CON UNA MEMBRANA Y BASADO EN LA DIFUSION. LA MEMBRANA TIENE UN LIQUIDO HIDROFOBO DENTRO DE LOS POROS DE LA MISMA. EL LIQUIDO ES IMPERMEABLE AL AGUA Y A LA SERTRALINA, SE MODIFICA POR DEGRADACION ENZIMATICA, SIENDO PERMEABLE AL AGUA Y A LA SERTRALINA. TAMBIEN SE REFIERE A UN PROCEDIMIENTO PARA LA PREPARACION. LA COMPOSICION SE PUEDE UTILIZAR PARA EL TRATAMIENTO DE LA ENFERMEDAD PSIQUIATRICA, EYACULACION PRECOZ, DEPENDENCIA QUIMICA
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US5142097P | 1997-07-01 | 1997-07-01 | |
US5141497P | 1997-07-01 | 1997-07-01 | |
US5140297P | 1997-07-01 | 1997-07-01 | |
US5149897P | 1997-07-01 | 1997-07-01 |
Publications (1)
Publication Number | Publication Date |
---|---|
PE88699A1 true PE88699A1 (es) | 1999-09-20 |
Family
ID=27489408
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE1998000572A PE88699A1 (es) | 1997-07-01 | 1998-06-26 | Formas de dosificacion de liberacion sostenida de sertralina |
Country Status (33)
Country | Link |
---|---|
US (1) | US6517866B1 (es) |
EP (1) | EP0999830A1 (es) |
JP (1) | JP2000514101A (es) |
KR (2) | KR100446366B1 (es) |
CN (1) | CN1256085C (es) |
AP (1) | AP1526A (es) |
AR (2) | AR015919A1 (es) |
AU (1) | AU739261B2 (es) |
BG (1) | BG103915A (es) |
BR (1) | BR9810403A (es) |
CA (1) | CA2290966C (es) |
CO (1) | CO4940402A1 (es) |
DZ (1) | DZ2546A1 (es) |
EA (1) | EA002482B1 (es) |
HK (1) | HK1026630A1 (es) |
HR (1) | HRP980379B1 (es) |
HU (1) | HUP0002296A3 (es) |
ID (1) | ID23503A (es) |
IL (2) | IL133080A0 (es) |
IS (1) | IS5265A (es) |
MY (1) | MY129175A (es) |
NO (1) | NO996518L (es) |
NZ (2) | NZ501251A (es) |
OA (1) | OA11245A (es) |
PA (1) | PA8454401A1 (es) |
PE (1) | PE88699A1 (es) |
PL (1) | PL337806A1 (es) |
SK (1) | SK180499A3 (es) |
TN (1) | TNSN98125A1 (es) |
TR (1) | TR199903280T2 (es) |
TW (1) | TWI241188B (es) |
UY (1) | UY25067A1 (es) |
WO (1) | WO1999001121A1 (es) |
Families Citing this family (65)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040208926A1 (en) * | 1997-07-01 | 2004-10-21 | Pfizer Inc | Solubilized sertraline compositions |
CA2327685C (en) * | 1998-04-03 | 2008-11-18 | Bm Research A/S | Controlled release composition |
US6706283B1 (en) * | 1999-02-10 | 2004-03-16 | Pfizer Inc | Controlled release by extrusion of solid amorphous dispersions of drugs |
IE990406A1 (en) | 1999-05-20 | 2000-12-27 | Elan Corp Plc | Multiparticulate controlled release selective serotonin reuptake inhibitor formulations. |
DZ3256A1 (fr) * | 1999-05-20 | 2000-11-30 | Elan Corp Plc | Preparations d'inhibiteurs specifiques du recaptage de la serotonine a liberation multiparticulaire regulee |
ES2393582T3 (es) | 1999-09-03 | 2012-12-26 | Apbi Holdings, Llc | Procedimiento de utilización de inhibidores de la recaptación de serotonina selectivos de inicio rápido de acción para el tratamiento de las disfunciones sexuales |
GB9923045D0 (en) * | 1999-09-29 | 1999-12-01 | Novartis Ag | New oral formulations |
JP2003518487A (ja) * | 1999-12-23 | 2003-06-10 | ファイザー・プロダクツ・インク | ヒドロゲル駆動型積層薬物製剤 |
US6620431B1 (en) * | 2000-04-17 | 2003-09-16 | Charles Signorino | Shellac film coatings providing release at selected pH and method |
US20030086972A1 (en) * | 2000-08-09 | 2003-05-08 | Appel Leah E. | Hydrogel-driven drug dosage form |
MXPA03001771A (es) | 2000-08-30 | 2003-06-04 | Pfizer Prod Inc | Formulaciones de liberacion sostenida para secretagogos de hormona del crecimiento. |
US6482440B2 (en) * | 2000-09-21 | 2002-11-19 | Phase 2 Discovery, Inc. | Long acting antidepressant microparticles |
SE0004671D0 (sv) | 2000-12-15 | 2000-12-15 | Amarin Dev Ab | Pharmaceutical formulation |
JP2002212062A (ja) * | 2001-01-24 | 2002-07-31 | Teijin Ltd | 遅延放出制御組成物 |
US20040076682A1 (en) * | 2001-02-15 | 2004-04-22 | Toshiyuki Kohzaki | Novel ophthalmic compositions |
NZ528957A (en) * | 2001-04-18 | 2005-05-27 | Nostrum Pharmaceuticals Inc | A novel coating for a sustained release pharmaceutical composition |
KR20040018463A (ko) * | 2001-07-16 | 2004-03-03 | 아스트라제네카 아베 | 양성자 펌프 억제제 및 제산제를 함유하는 제약 제제 |
EP2957281A1 (en) | 2001-09-21 | 2015-12-23 | Egalet Ltd. | Polymer release system |
US20040253310A1 (en) | 2001-09-21 | 2004-12-16 | Gina Fischer | Morphine polymer release system |
US20040213848A1 (en) * | 2001-09-28 | 2004-10-28 | Shun-Por Li | Modified release dosage forms |
US7005138B2 (en) * | 2001-12-21 | 2006-02-28 | Duramed Pharmaceuticals, Inc. | Method of systematically delivering SSRIs |
US7670612B2 (en) | 2002-04-10 | 2010-03-02 | Innercap Technologies, Inc. | Multi-phase, multi-compartment capsular delivery apparatus and methods for using same |
US20100189797A1 (en) | 2002-06-10 | 2010-07-29 | Julien Mendlewicz | Oral antidepressant formulation |
US20050226926A1 (en) * | 2002-07-25 | 2005-10-13 | Pfizer Inc | Sustained-release tablet composition of pramipexole |
WO2004024130A2 (en) * | 2002-09-16 | 2004-03-25 | Sepracor, Inc. | TREATMENT OF CNS DISORDERS WITH trans 4-(3,4-DICHLOROPHENYL)-1,2,3,4-TETRAHYDRO-N-METHYL-1-NAPTHALENAMINE |
US20040220153A1 (en) * | 2002-09-24 | 2004-11-04 | Jost-Price Edward Roydon | Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines |
CA2415154C (en) * | 2002-12-24 | 2009-06-16 | Biovail Laboratories Inc. | Modified release formulations of selective serotonin re-uptake inhibitors |
WO2004065348A1 (en) * | 2003-01-23 | 2004-08-05 | Pfizer Products Inc. | Pharmaceutically acceptable salts of sertraline and pharmaceutical compositions thereof |
US20040224876A1 (en) * | 2003-02-14 | 2004-11-11 | Jost-Price Edward Roydon | Combination therapy for the treatment of immunoinflammatory disorders |
EP2301526B1 (en) * | 2003-03-26 | 2016-03-23 | Egalet Ltd. | Morphine controlled release system |
MXPA05010636A (es) * | 2003-04-04 | 2005-12-12 | Pharmacia Corp | Comprimidos de multiparticulas preparados por compresion de liberacion oral prolongada. |
AU2004231362B2 (en) | 2003-04-24 | 2009-11-12 | Jagotec Ag | Delayed release tablet with defined core geometry |
US7186863B2 (en) | 2003-05-23 | 2007-03-06 | Transform Pharmaceuticals, Inc. | Sertraline compositions |
AP1899A (en) * | 2003-08-08 | 2008-10-10 | Biovail Lab Int Srl | Modified-release tablet of bupropion hydrochloride |
NZ546902A (en) * | 2003-11-04 | 2010-02-26 | Cipla Ltd | Process for the preparation of polymorphs of selective serotonin reuptake inhibitor |
TW201240679A (en) * | 2004-03-12 | 2012-10-16 | Capsugel Belgium Nv | Pharmaceutical formulations |
KR100772980B1 (ko) * | 2004-04-01 | 2007-11-02 | 한미약품 주식회사 | 메트포르민의 경구투여용 서방성 제제 |
US20050232911A1 (en) * | 2004-04-19 | 2005-10-20 | Schreiber Brian D | Prevention and treatment of metabolic abnormalities associated with excess intramyocellular lipid |
ITMI20041295A1 (it) * | 2004-06-25 | 2004-09-25 | Cosmo Spa | Composizioni farmaceutiche antimicrobiche orali |
CN101849921A (zh) | 2004-08-13 | 2010-10-06 | 贝林格尔·英格海姆国际有限公司 | 包含普拉克索或其可药用盐的延长释放片剂 |
KR100920856B1 (ko) * | 2004-11-30 | 2009-10-09 | (주)아모레퍼시픽 | 선택적 세로토닌 재흡수 억제제의 연장방출 제제 및 그제조방법 |
WO2006072878A1 (en) * | 2005-01-07 | 2006-07-13 | Ranbaxy Laboratories Limited | Oral dosage forms of sertraline having controlled particle size and processes for their preparation |
US20080274183A1 (en) * | 2005-02-04 | 2008-11-06 | Phillip Michael Cook | Thermoplastic articles containing a medicament |
US20080213381A1 (en) * | 2005-03-14 | 2008-09-04 | Pharmaceutical Industries Limited | Oral Drug Delivery System |
NZ563846A (en) * | 2005-06-03 | 2010-03-26 | Egalet As | A drug delivery system for delivering active substances dispersed in a dispersion medium |
US8747897B2 (en) * | 2006-04-27 | 2014-06-10 | Supernus Pharmaceuticals, Inc. | Osmotic drug delivery system |
US7893053B2 (en) * | 2006-06-16 | 2011-02-22 | Theracos, Inc. | Treating psychological conditions using muscarinic receptor M1 antagonists |
ES2400446T5 (es) | 2006-08-03 | 2017-03-13 | Horizon Pharma Ag | Tratamiento con glucocorticoides de liberación retardada de una enfermedad reumática |
CA2930487A1 (en) * | 2007-01-16 | 2008-07-24 | Egalet Ltd. | Use of i) a polyglycol and ii) an active drug substance for the preparation of a pharmaceutical composition for i)mitigating the risk of alcohol induced dose dumping and/or ii) reducing the risk of drug abuse |
WO2008148798A2 (en) | 2007-06-04 | 2008-12-11 | Egalet A/S | Controlled release pharmaceutical compositions for prolonged effect |
WO2009034431A2 (en) | 2007-09-10 | 2009-03-19 | Pfizer Inc. | Controlled-release dosage forms for varenicline |
US20110142905A1 (en) * | 2008-08-14 | 2011-06-16 | Bioneer A/S | Coated tablets with remaining degradation surface over the time |
DE102008051572A1 (de) | 2008-09-05 | 2010-03-11 | Maria Clementine Martin Klosterfrau Vertriebsgesellschaft Mbh | Herstellung von Phosphatbindern und auf diese Weise hergestellte Phosphatbinder |
AU2008243202B2 (en) * | 2008-11-11 | 2015-08-20 | Cosmo Technologies Ltd | Oral antimicrobial pharmaceutical compositions |
WO2010089132A1 (en) | 2009-02-06 | 2010-08-12 | Egalet A/S | Immediate release composition resistant to abuse by intake of alcohol |
NZ597283A (en) | 2009-06-24 | 2013-07-26 | Egalet Ltd | Controlled release formulations |
WO2011057133A1 (en) | 2009-11-09 | 2011-05-12 | Spotlight Technology Partners Llc | Fragmented hydrogels |
NZ599524A (en) | 2009-11-09 | 2014-04-30 | Spotlight Technology Partners Llc | Polysaccharide based hydrogels |
US9549899B2 (en) | 2012-07-06 | 2017-01-24 | Egalet Ltd. | Abuse deterrent pharmaceutical compositions for controlled release |
JP6041823B2 (ja) | 2013-03-16 | 2016-12-14 | ファイザー・インク | トファシチニブの経口持続放出剤形 |
WO2016020936A2 (en) * | 2014-07-21 | 2016-02-11 | Patel Jayendrakumar Dasharathlal | A novel oral gastroretentive pharmaceutical dosage form |
CN104402705B (zh) * | 2014-11-04 | 2017-04-12 | 成都理工大学 | 球形柠檬酸钙及其制备方法和应用 |
JP6455293B2 (ja) * | 2015-04-21 | 2019-01-23 | ニプロ株式会社 | セルトラリン及び/又はその薬学上許容しうる塩を含む製剤 |
CN111315241B (zh) * | 2017-10-05 | 2022-04-26 | 普拉克生化公司 | 乳酸盐粉末及其制备方法 |
CN109432038A (zh) * | 2018-12-28 | 2019-03-08 | 乐普制药科技有限公司 | 一种含有盐酸舍曲林的肠溶片剂及其制备方法 |
Family Cites Families (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4536518A (en) * | 1979-11-01 | 1985-08-20 | Pfizer Inc. | Antidepressant derivatives of cis-4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine |
DK150008C (da) | 1981-11-20 | 1987-05-25 | Benzon As Alfred | Fremgangsmaade til fremstilling af et farmaceutisk oralt polydepotpraeparat |
US5112619A (en) | 1985-11-12 | 1992-05-12 | Eli Lilly And Company | Orally administerable sustained release pharmaceutical formulation |
US4847092A (en) | 1985-11-12 | 1989-07-11 | Eli Lilly And Company | Orally administerable sustained release pharmaceutical formulations |
US4797286A (en) | 1985-11-12 | 1989-01-10 | Eli Lilly And Company | Orally administerable sustained release pharmaceutical formulations |
US4803076A (en) | 1986-09-04 | 1989-02-07 | Pfizer Inc. | Controlled release device for an active substance |
DE3700420A1 (de) | 1986-12-22 | 1988-07-07 | Efka Werke Kiehn Gmbh Fritz | Tabakerzeugnis fuer die selbstverfertigung einer zigarette, insbesondere filter-zigarette |
US5135947A (en) | 1987-04-09 | 1992-08-04 | Eli Lilly And Company | 1-phenyl-3-naphthalenyloxypropanamines and their use as selective serotonin reuptake inhibitors |
US4839104A (en) | 1987-06-11 | 1989-06-13 | Pfizer, Inc. | Process for preparing sertraline intermediates |
US4777288A (en) | 1987-06-11 | 1988-10-11 | Pfizer Inc. | Process for preparing a 4,4-diphenylbutanoic acid derivative |
US4792448A (en) | 1987-06-11 | 1988-12-20 | Pfizer Inc. | Generic zero order controlled drug delivery system |
US4971998A (en) | 1987-10-22 | 1990-11-20 | Massachusetts Institute Of Technology | Methods for treating the premenstrual or late luteal phase syndrome |
US4876282A (en) | 1987-11-25 | 1989-10-24 | Eli Lilly And Company | 1-Phenylalkylamines as selective serotonin uptake inhibitors |
US4855500A (en) | 1988-05-04 | 1989-08-08 | Pfizer Inc. | Process for preparing a ketimine |
US5026707A (en) | 1988-05-23 | 1991-06-25 | Eli Lilly And Company | Ring-substituted 2-amino-1,2,3,4-tetrahydronaphthalenes |
IL91398A (en) * | 1988-08-30 | 1994-05-30 | Pfizer | A device for the controlled release of pneumatic substances, including the active substance, surrounded by an asymmetric membrane |
IL114715A (en) | 1989-02-27 | 1997-01-10 | Lilly Co Eli | Intermediate compounds for ring-substituted 2-amino-1, 2, 3, 4-tetrahydronaphthalenes and 3-aminochromanes |
US4981870A (en) | 1989-03-07 | 1991-01-01 | Pfizer Inc. | Use of 4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine derivatives in the treatment of psychosis, inflammation and as immunosuppressants |
US4983401A (en) | 1989-05-22 | 1991-01-08 | Kinaform Technology, Inc. | Sustained release pharmaceutical preparations having pH controlled membrane coatings |
US4940731A (en) | 1989-08-30 | 1990-07-10 | Pfizer Inc. | Method of treating premature ejaculation using sertraline |
US5130338A (en) | 1989-08-30 | 1992-07-14 | Pfizer Inc. | Method of treating chemical dependencies using sertraline |
ATE96999T1 (de) | 1989-08-30 | 1993-11-15 | Pfizer | Verwendung von sertralin zur behandlung von abhaengigkeiten von chemischen stoffen. |
US4962128A (en) | 1989-11-02 | 1990-10-09 | Pfizer Inc. | Method of treating anxiety-related disorders using sertraline |
AU8072691A (en) | 1990-06-28 | 1992-01-23 | Beecham Group Plc | Pharmaceutical preparations |
DK0542926T3 (da) | 1990-08-07 | 1995-05-15 | Pfizer | Brug af grænsefladepolymeriserede membraner i frigivelsesanordninger |
AU8629691A (en) | 1990-08-09 | 1992-03-02 | Massachusetts Institute Of Technology | Method for treating the premenstrual or late luteal phase syndrome |
US5104899A (en) | 1990-08-13 | 1992-04-14 | Sepracor, Inc. | Methods and compositions for treating depression using optically pure fluoxetine |
US5371092A (en) | 1990-11-24 | 1994-12-06 | Beecham Group, P.L.C. | Use of paroxetine for the treatment of senile dementia, bulimia, migraine or anorexia |
ATE197145T1 (de) | 1991-02-08 | 2000-11-15 | Lilly Co Eli | Ringsubstituierte 2-amino-1,2,3,4- tetrahydronaphtahline und 3-aminochromane |
AU1919592A (en) | 1991-04-16 | 1992-11-17 | National Institutes Of Health | Method of treating trichotillomania and onychophagia |
US5196607A (en) | 1992-02-14 | 1993-03-23 | Pfizer Inc. | Process for preparing ketone enantiomer |
AU668386B2 (en) | 1992-03-25 | 1996-05-02 | Depomed Systems, Incorporated | Alkyl-substituted cellulose-based sustained-release oral drug dosage forms |
US5518730A (en) | 1992-06-03 | 1996-05-21 | Fuisz Technologies Ltd. | Biodegradable controlled release flash flow melt-spun delivery system |
US5248699A (en) | 1992-08-13 | 1993-09-28 | Pfizer Inc. | Sertraline polymorph |
US6440457B1 (en) | 1993-05-27 | 2002-08-27 | Alza Corporation | Method of administering antidepressant dosage form |
IE930485A1 (en) | 1993-06-28 | 1994-12-28 | Hemisphere Ltd | Antidepressant agents with a rapid onset of action |
US5597826A (en) | 1994-09-14 | 1997-01-28 | Pfizer Inc. | Compositions containing sertraline and a 5-HT1D receptor agonist or antagonist |
EP0782445B1 (en) | 1994-09-19 | 2002-03-13 | Dupont Pharmaceuticals Company | Combination of an opioid antagonist and a selective serotonin reuptake inhibitor for treatment of alcoholism and alcohol dependence |
PT768083E (pt) | 1995-07-17 | 2003-08-29 | Pfizer | Sertralina para o tratamento de doentes pos-enfarte miocardico |
GB9514842D0 (en) | 1995-07-20 | 1995-09-20 | Smithkline Beecham Plc | Novel formulation |
CN1494907A (zh) | 1996-03-25 | 2004-05-12 | 治疗疼痛的药物组合物 | |
ZA97976B (en) * | 1996-04-05 | 1997-08-18 | Alza Corp | Uniform drug delivery theraphy. |
US5741807A (en) | 1996-09-27 | 1998-04-21 | Cytos Pharmaceuticals, L.P. | Histidine compositions and methods for treating or preventing infectious and non-infectious diarrheas |
US6590083B1 (en) | 1999-04-16 | 2003-07-08 | Ortho-Mcneil Pharmaceutical, Inc. | Ketolide antibacterials |
-
1998
- 1998-06-15 EP EP98923020A patent/EP0999830A1/en not_active Withdrawn
- 1998-06-15 SK SK1804-99A patent/SK180499A3/sk unknown
- 1998-06-15 WO PCT/IB1998/000934 patent/WO1999001121A1/en active Application Filing
- 1998-06-15 NZ NZ501251A patent/NZ501251A/en unknown
- 1998-06-15 US US09/380,897 patent/US6517866B1/en not_active Expired - Fee Related
- 1998-06-15 ID IDW991704A patent/ID23503A/id unknown
- 1998-06-15 TR TR1999/03280T patent/TR199903280T2/xx unknown
- 1998-06-15 CN CNB988066963A patent/CN1256085C/zh not_active Expired - Fee Related
- 1998-06-15 IL IL13308098A patent/IL133080A0/xx unknown
- 1998-06-15 KR KR10-2003-7002633A patent/KR100446366B1/ko not_active IP Right Cessation
- 1998-06-15 AU AU75449/98A patent/AU739261B2/en not_active Ceased
- 1998-06-15 JP JP11506775A patent/JP2000514101A/ja active Pending
- 1998-06-15 KR KR10-1999-7012073A patent/KR100412327B1/ko not_active IP Right Cessation
- 1998-06-15 CA CA002290966A patent/CA2290966C/en not_active Expired - Fee Related
- 1998-06-15 PL PL98337806A patent/PL337806A1/xx unknown
- 1998-06-15 EA EA199900964A patent/EA002482B1/ru not_active IP Right Cessation
- 1998-06-15 HU HU0002296A patent/HUP0002296A3/hu unknown
- 1998-06-15 NZ NZ513456A patent/NZ513456A/xx unknown
- 1998-06-15 IL IL15233098A patent/IL152330A0/xx unknown
- 1998-06-15 BR BR9810403-9A patent/BR9810403A/pt not_active Application Discontinuation
- 1998-06-25 TW TW087110253A patent/TWI241188B/zh not_active IP Right Cessation
- 1998-06-25 AP APAP/P/1998/001281A patent/AP1526A/en active
- 1998-06-26 PE PE1998000572A patent/PE88699A1/es not_active Application Discontinuation
- 1998-06-29 AR ARP980103148A patent/AR015919A1/es not_active Application Discontinuation
- 1998-06-29 UY UY25067A patent/UY25067A1/es not_active IP Right Cessation
- 1998-06-29 MY MYPI98002948A patent/MY129175A/en unknown
- 1998-06-30 DZ DZ980156A patent/DZ2546A1/xx active
- 1998-06-30 PA PA19988454401A patent/PA8454401A1/es unknown
- 1998-06-30 TN TNTNSN98125A patent/TNSN98125A1/fr unknown
- 1998-07-01 HR HR980379A patent/HRP980379B1/xx not_active IP Right Cessation
- 1998-07-01 CO CO98037140A patent/CO4940402A1/es unknown
-
1999
- 1999-11-23 BG BG103915A patent/BG103915A/xx unknown
- 1999-11-23 IS IS5265A patent/IS5265A/is unknown
- 1999-12-23 OA OA9900305A patent/OA11245A/en unknown
- 1999-12-28 NO NO996518A patent/NO996518L/no not_active Application Discontinuation
-
2000
- 2000-09-19 HK HK00105878A patent/HK1026630A1/xx not_active IP Right Cessation
-
2006
- 2006-01-03 AR ARP060100016A patent/AR065827A2/es unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE88699A1 (es) | Formas de dosificacion de liberacion sostenida de sertralina | |
PA8509001A1 (es) | Forma de dosificacion de farmacos accionada por un hidrogel | |
PA8524901A1 (es) | Forma de dosificaciòn de fàrmaco activada por hidrogel | |
GT199900203A (es) | Composiciones de celecoxib. | |
PE20000721A1 (es) | Articulo absorbente que incluye un agente modificador de heces basado en calcio | |
DK0558475T3 (da) | Fremgangsmåde og sammensætning til styret afgivelse af biologisk aktive midler | |
PT1165053E (pt) | Formas de dosagem de dispersao rapida contendo gelatina de peixe | |
AR055552A1 (es) | Preparacion topica refrescante para parches y metodos para utilizar la misma | |
ES2159591T3 (es) | Composicion de liberacion controlada. | |
UY24210A1 (es) | Composicion de gel o de barra antitranspirante libre de pegajosidad, clara o translucida y metodo de fabricacion | |
CO4970819A1 (es) | Tratamiento de disfuncion sexual femenina en una hembra humana | |
CO5210862A1 (es) | Formas de dosificacion y metodos para proporcionar efectiva terapia de reboxetina con dosificacion de una vez al dia | |
PE20050066A1 (es) | Formulaciones farmaceuticas liquidas de palonosetron | |
HK1060045A1 (en) | Formulations comprising ibuprofen and diphenhydramine and the use thereof for the treatment of sleepdisturbances | |
ES2059786T3 (es) | Composicion blanqueante. | |
CO5251434A1 (es) | Composicion de liberacion controlada | |
AR028705A1 (es) | Bis-arilsulfonas | |
ES2182507T3 (es) | Sistema terapeutico que puede ser activado por la humedad. | |
BR0003231A (pt) | Catalisadores de leito fixo | |
BRPI0017528B8 (pt) | uso de uma composição contendo sal de cetotifeno | |
AR029688A1 (es) | Composiciones de liberacion retardada de matriz antibiotica de quinolona para administracion oral, y procedimiento para su fabricacion | |
PE84399A1 (es) | Formas de dosificacion de sertralina de liberacion retardada | |
BR0009771A (pt) | Utilização de derivados de bisindóis indigóides capazes de penetrarem na membrana de células | |
PE20010568A1 (es) | Formulaciones orales de liberacion controlada | |
PE20070464A1 (es) | Forma farmaceutica con liberacion sostenida independiente del ph de un ingrediente activo, para ingredientes activos que tienen una solubilidad que depende en gran medida del ph |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant, registration | ||
FD | Application declared void or lapsed |